Management of small-cell cancer of the lung

[1]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[2]  J. Crowley,et al.  Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. , 1991, Chest.

[3]  R. Ginsberg,et al.  Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. , 1991, The Journal of thoracic and cardiovascular surgery.

[4]  H. Hansen,et al.  Second-line chemotherapy in small cell lung cancer. , 1990, Cancer treatment reviews.

[5]  R. Leonard,et al.  Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer. , 1990, Cancer research.

[6]  S. Steinberg,et al.  Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Souhami,et al.  Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. , 1990, British Journal of Cancer.

[8]  D. Ettinger,et al.  The clinical significance of variant-morphology small-cell carcinoma of the lung. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Hansen,et al.  Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. , 1990, Journal of the National Cancer Institute.

[10]  Mark R. Green.  Phase III chemotherapy trials in small cell lung cancer , 1989 .

[11]  R. Ginsberg,et al.  Staging and prognostic factors in small cell lung cancer: a consensus report , 1989 .

[12]  R. Arriagada,et al.  Thoracic radiotherapy in small cell lung cancer: rationale for timing and fractionation , 1989 .

[13]  D G Lowe,et al.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Propert,et al.  A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Fayers,et al.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. , 1989, British Journal of Cancer.

[16]  M. Partridge,et al.  Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. , 1989, British Journal of Cancer.

[17]  R. Steele,et al.  Histopathologic classification of small cell lung cancer changing concepts and terminology , 1988, Cancer.

[18]  C. Mountain.  Staging of lung cancer: The new international system , 1987 .

[19]  F. Hirsch,et al.  The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Cantell,et al.  Natural alpha interferon as maintenance therapy for small cell lung cancer , 1991 .

[21]  M. Sullivan,et al.  Quality of life during chemotherapy for small cell lung cancer. I. An evaluation with generic health measures. , 1991, Acta oncologica.

[22]  H. Hansen,et al.  Chemotherapy of small cell lung cancer. , 1991, European journal of cancer.

[23]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.